

Literaturverzeichnis

(Anmerkung: Die Ordnung der Literatur bei mehreren Arbeiten des gleichen Erstautors ergibt sich aus der alphabetischen Reihenfolge der Co-Autoren)

Abraham HD, Degli-Esposti S and Marino L (1999) Seroprevalence of Hepatitis C in a Sample of Middle Class Substance Abusers. *J Addict Dis* 18: pp 77-87.

Adams F (1984) Neuropsychiatric Manifestations of Human Leukocyte Interferon Therapy in Patients With Cancer. *J Am Med Assn* 252: pp 938-941.

Amaraa R, Mareckova H, Urbanek P and Fucikova T (2002) Production of Interleukins 10 and 12 by Activated Peripheral Blood Monocytes/Macrophages in Patients Suffering From Chronic Hepatitis C Virus Infection With Respect to the Response to Interferon and Ribavirin Treatment. *Immunol Lett* 83: pp 209-214.

AMDP and CIPS (1990) *Rating Scales for Psychiatry. European Edition*. Beltz Test GmbH, Weinheim.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th edn. 1994. Washington,DC, APA.

Anton C, Trifan A, Stanciu C, Stanciu G O and Malgarinos G (2000) [Seizures During the Treatment With Interferon for Chronic C Hepatitis]. *Rev Med Chir Soc Med Nat Iasi* 104: pp 135-137.

Asadullah K, Sterry W and Trefzer U (2002) Cytokine Therapy in Dermatology. *Exp Dermatol* 11: pp 97-106.

Backmund M, Meyer K, Von Zielonka M and Eichenlaub D (2001) Treatment of Hepatitis C Infection in Injection Drug Users. *Hepatology* 34: pp 188-193.

Backmund M, Meyer K, Wachtler M and Eichenlaub D (2003) Hepatitis C Virus Infection in Injection Drug Users in Bavaria: Risk Factors for Seropositivity. *Eur J Epidemiol* 18: pp 563-568.

- Banks WA, Farr S A and Morley J E (2002) Entry of Blood-Borne Cytokines into the Central Nervous System: Effects on Cognitive Processes. *Neuroimmunomodulation* 10: pp 319-327.
- Banks WA, Kastin A J and Broadwell R D (1995a) Passage of Cytokines Across the Blood-Brain Barrier. *Neuroimmunomodulation* 2: pp 241-248.
- Banks WA, Ortiz L, Plotkin S R and Kastin A J (1991) Human Interleukin (IL) 1 Alpha, Murine IL-1 Alpha and Murine IL-1 Beta Are Transported From Blood to Brain in the Mouse by a Shared Saturable Mechanism. *J Pharmacol Exp Ther* 259: pp 988-996.
- Banks WA, Plotkin S R and Kastin A J (1995b) Permeability of the Blood-Brain Barrier to Soluble Cytokine Receptors. *Neuroimmunomodulation* 2: pp 161-165.
- Baraczka K, Nekam K, Pozsonyi T, Jakab L, Szongoth M and Sesztak M (2001) Concentration of Soluble Adhesion Molecules (SVCAM-1, SICAM-1 and SL-Selectin) in the Cerebrospinal Fluid and Serum of Patients With Multiple Sclerosis and Systemic Lupus Erythematosus With Central Nervous Involvement. *Neuroimmunomodulation* 9: pp 49-54.
- Baratt, E. S. (1965) Factor analysis of some psychometric measures of impulsiveness and anxiety. *Psychological Reports* 16, 547-554
- Beck AT, Kovacs M and Weissman A (1979) Assessment of Suicidal Intention: the Scale for Suicide Ideation. *J Consult Clin Psychol* 47: pp 343-352.
- Black PH and Garbutt L D (2002) Stress, Inflammation and Cardiovascular Disease. *J Psychosom Res* 52: pp 1-23.
- Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F and Maes M (2002b) Depression Induced by Treatment With Interferon-Alpha in Patients Affected by Hepatitis C Virus. *J Affect Disord* 72: pp 237-241.
- Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H and Maes M (2002a) Increased Depressive Ratings in Patients With Hepatitis C Receiving Interferon-Alpha-Based Immunotherapy Are Related to Interferon-Alpha-Induced Changes in the Serotonergic System. *J Clin Psychopharmacol* 22: pp 86-90.

- Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, Almerighi C, Levrero M, Egyed B, Bosmans E, Meltzer H Y and Maes M (2001) Immunotherapy With Interferon-Alpha in Patients Affected by Chronic Hepatitis C Induces an Intercorrelated Stimulation of the Cytokine Network and an Increase in Depressive and Anxiety Symptoms. *Psychiatry Res* 105: pp 45-55.
- Brandt ER, Mackay I R, Hertzog P J, Cheetham B F, Sherritt M and Bernard C C (1993) Molecular Detection of Interferon-Alpha Expression in Multiple Sclerosis Brain. *J Neuroimmunol* 44: pp 1-5.
- Brassard DL, Grace M J and Bordens R W (2002) Interferon-Alpha As an Immunotherapeutic Protein. *J Leukoc Biol* 71: pp 565-581.
- Brierley MM and Fish E N (2002) Review: IFN-Alpha/Beta Receptor Interactions to Biologic Outcomes: Understanding the Circuitry. *J Interferon Cytokine Res* 22: pp 835-845.
- Broers B, Junet C, Bourquin M, Deglon J J, Perrin L and Hirschel B (1998) Prevalence and Incidence Rate of HIV, Hepatitis B and C Among Drug Users on Methadone Maintenance Treatment in Geneva Between 1988 and 1995. *AIDS* 12: pp 2059-2066.
- Brown JE, Brown R F, Miller R M, Dunn S M, King M T, Coates A S and Butow P N (2000) Coping With Metastatic Melanoma: the Last Year of Life. *Psychooncology* 9: pp 283-292.
- Buss, A. H. and Durkee, A. (1957) An inventory for assessing different kinds of hostility. *Journal of Consulting Psychology*: pp 21, 343-349.
- Cabrera Gomez JA, Cordero G, Jr., Fernandez L O, Reyes G B, Romero G K, Simon C J, Feas C R, Gonzalez Q A, Alfaro C, I, Del Pino F M (1993) Treatment of Schizophrenic Disorder, Paranoid Type, With Intramuscular Recombinant Alpha-2b Interferon. *Biotherapy* 7: pp 27-37.
- Capuron L and Dantzer R (2003) Cytokines and Depression: the Need for a New Paradigm. *Brain Behav Immun* 17 Suppl 1: pp S119-S124.

Capuron L, Gumnick J F, Musselman D L, Lawson D H, Reemsnyder A, Nemeroff C B and Miller A H (2002a) Neurobehavioral Effects of Interferon-Alpha in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions. *Neuropsychopharmacology* 26: pp 643-652.

Capuron L, Raison C L, Musselman D L, Lawson D H, Nemeroff C B and Miller A H (2003) Association of Exaggerated HPA Axis Response to the Initial Injection of Interferon-Alpha With Development of Depression During Interferon-Alpha Therapy. *Am J Psychiatry* 160: pp 1342-1345.

Capuron L and Ravaud A (1999) Prediction of the Depressive Effects of Interferon Alfa Therapy by the Patient's Initial Affective State. *N Engl J Med* 340: pp 1370.

Capuron L, Ravaud A and Dantzer R (2000) Early Depressive Symptoms in Cancer Patients Receiving Interleukin 2 and/or Interferon Alfa-2b Therapy. *J Clin Oncol* 18: pp 2143-2151.

Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M and Neveu P J (2001) Association Between Immune Activation and Early Depressive Symptoms in Cancer Patients Treated With Interleukin-2-Based Therapy. *Psychoneuroendocrinology* 26: pp 797-808.

Capuron L, Ravaud A, Neveu P J, Miller A H, Maes M and Dantzer R (2002 b) Association Between Decreased Serum Tryptophan Concentrations and Depressive Symptoms in Cancer Patients Undergoing Cytokine Therapy. *Mol Psychiatry* 7: pp 468-473.

Caraceni A, Gangeri L, Martini C, Belli F, Brunelli C, Baldini M, Mascheroni L, Lenisa L and Cascinelli N (1998) Neurotoxicity of Interferon-Alpha in Melanoma Therapy: Results From a Randomized Controlled Trial. *Cancer* 83: pp 482-489.

Castera L, Zigante F, Bastie A, Buffet C, Dhumeaux D and Hardy P (2002) Incidence of Interferon Alfa-Induced Depression in Patients With Chronic Hepatitis C. *Hepatology* 35: pp 978-979.

Chang TT, Lin H, Yen Y S and Wu H L (1993) Hepatitis B and Hepatitis C Among Institutionalized Psychiatric Patients in Taiwan. *J Med Virol* 40: pp 170-173.

- Cirelli R and Tyring S K (1995) Major Therapeutic uses of Interferons. *Clin Immunother* 3[1]: pp27-87.
- Cividini A, Pistorio A, Regazzetti A, Cerino A, Tinelli C, Mancuso A, Ribola M, Galli M L, Agnusdei A, Leone M, Silini E and Mondelli M U (1997a) Hepatitis C Virus Infection Among Institutionalised Psychiatric Patients: a Regression Analysis of Indicators of Risk. *J Hepatol* 27: pp 455-463.
- Colamonici OR and Pfeffer L M (1991) Structure of the Human Interferon Alpha Receptor. *Pharmacol Ther* 52: pp 227-233.
- Crofts N, Jolley D, Kaldor J, van B, I and Wodak A (1997a) Epidemiology of Hepatitis C Virus Infection Among Injecting Drug Users in Australia. *J Epidemiol Community Health* 51: pp 692-697.
- Crofts N, Nigro L, Oman K, Stevenson E and Sherman J (1997b) Methadone Maintenance and Hepatitis C Virus Infection Among Injecting Drug Users. *Addiction* 92: pp 999-1005.
- Dafny N, Prieto-Gomez B and Reyes-Vazquez C (1985) Does the Immune System Communicate With the Central Nervous System? Interferon Modifies Central Nervous Activity. *J Neuroimmunol* 9: pp 1-12.
- Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen H T and Olsen J H (2003) Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Tract Bleeding: a Population-Based Cohort Study. *Arch Intern Med* 163: pp 59-64.
- Dantzer R (2001) Cytokine-Induced Sickness Behavior: Mechanisms and Implications. *Ann N Y Acad Sci* 933: pp 222-234.
- David M (1995) Transcription Factors in Interferon Signaling. *Pharmacol Ther* 65: pp 149-161.
- David M (2002) Signal Transduction by Type I Interferons. *Biotechniques Suppl*: pp 58-65.

- De Andrea M, Ravera R, Gioia D, Gariglio M and Landolfo S (2002) The Interferon System: an Overview. *Eur J Paediatr Neurol* 6 Suppl A: pp A41-A46.
- Del Maschio A, De Luigi A, Martin-Padura I, Brockhaus M, Bartfai T, Fruscella P, Adorini L, Martino G, Furlan R, De Simoni M G and Dejana E (1999) Leukocyte Recruitment in the Cerebrospinal Fluid of Mice With Experimental Meningitis Is Inhibited by an Antibody to Junctional Adhesion Molecule (JAM). *J Exp Med* 190: pp 1351-1356.
- Derogatis LR, Morrow G R, Fetting J, Penman D, Piasetsky S, Schmale A M, Henrichs M and Carnicke C L, Jr. (1983) The Prevalence of Psychiatric Disorders Among Cancer Patients. *JAMA* 249: pp 751-757.
- Diamantis I, Bassetti S, Erb P, Ladewig D, Gyr K and Battegay M (1997) High Prevalence and Coinfection Rate of Hepatitis G and C Infections in Intravenous Drug Addicts. *J Hepatol* 26: pp 794-797.
- Dieperink E, Ho S B, Thuras P and Willenbring M L (2003) A Prospective Study of Neuropsychiatric Symptoms Associated With Interferon-Alpha-2b and Ribavirin Therapy for Patients With Chronic Hepatitis C. *Psychosomatics* 44: pp 104-112.
- Dieperink E, Willenbring M and Ho S B (2000) Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review. *Am J Psychiatry* 157: pp 867-876.
- DiMatteo MR, Lepper H S and Croghan T W (2000) Depression Is a Risk Factor for Noncompliance With Medical Treatment: Meta-Analysis of the Effects of Anxiety and Depression on Patient Adherence. *Arch Intern Med* 160: pp 2101-2107.
- Dinwiddie SH, Shicker L and Newman T (2003) Prevalence of Hepatitis C Among Psychiatric Patients in the Public Sector. *Am J Psychiatry* 160: pp 172-174.
- Dore GJ, Law M, MacDonald M and Kaldor J M (2003) Epidemiology of Hepatitis C Virus Infection in Australia. *J Clin Virol* 26: pp 171-184.
- Dunn AJ (1992) Endotoxin-Induced Activation of Cerebral Catecholamine and Serotonin Metabolism: Comparison With Interleukin-1. *J Pharmacol Exp Ther* 261: pp 964-969.

Dunn AJ (2000) Cytokine Activation of the HPA Axis. *Ann N Y Acad Sci* 917: pp 608-617.

Dunn AJ, Wang J and Ando T (1999) Effects of Cytokines on Cerebral Neurotransmission. Comparison With the Effects of Stress. *Adv Exp Med Biol* 461: pp 117-127.

Dussaix E, Lebon P, Ponsot G, Huault G and Tardieu M (1985) Intrathecal Synthesis of Different Alpha-Interferons in Patients With Various Neurological Diseases. *Acta Neurol Scand* 71: pp 504-509.

EASL (1999) EASL Consensus Statement – International Consensus Conference on Hepatitis C. *J Hepatol* 30: pp 956-961.

Eggermont AM, Keilholz U, Testori A, Cook M, Lienard D and Ruiter D J (2001) The EORTC Melanoma Group Translational Research Program on Prognostic Factors and Ultrastaging in Association With the Adjuvant Therapy Trials in Stage II and Stage III Melanoma. European Organization for Research and Treatment of Cancer. *Ann Surg Oncol* 8: pp 38S-40S.

Eggermont AM and Punt C J (2003) Does Adjuvant Systemic Therapy With Interferon-Alpha for Stage II-III Melanoma Prolong Survival? *Am J Clin Dermatol* 4: pp 531-536.

Engelhardt B, Conley F K and Butcher E C (1994) Cell Adhesion Molecules on Vessels During Inflammation in the Mouse Central Nervous System. *J Neuroimmunol* 51: pp 199-208.

Estrada AL (2002) Epidemiology of HIV/AIDS, Hepatitis B, Hepatitis C, and Tuberculosis Among Minority Injection Drug Users. *Public Health Rep* 117 Suppl 1: pp S126-S134.

Fattovich G, Giustina G, Favarato S and Ruol A (1996) A Survey of Adverse Events in 11,241 Patients With Chronic Viral Hepatitis Treated With Alfa Interferon. *J Hepatol* 24: pp 38-47.

Fontana RJ (2000) Neuropsychiatric Toxicity of Antiviral Treatment in Chronic Hepatitis C. *Dig Dis* 18: pp 107-116.

- Frei K, Piani D, Pfister HW and Fontana A (1993) Immune-Mediated Injury in Bacterial Meningitis. *Int Rev Exp Pathol* 34 PtB: pp 183-192.
- Fried MW, Shiffman M L, Reddy K R, Smith C, Marinos G, Goncales F L, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J and Yu J (2002) Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection. *N Engl J Med* 347: pp 975-982.
- Galeazzi B, Tufano A, Barbierato E and Bortolotti F (1995) Hepatitis C Virus Infection in Italian Intravenous Drug Users: Epidemiological and Clinical Aspects. *Liver* 15: pp 209-212.
- Gattaz WF, Dalgalarondo P and Schroder H C (1992) Abnormalities in Serum Concentrations of Interleukin-2, Interferon-Alpha and Interferon-Gamma in Schizophrenia Not Detected. *Schizophr Res* 6: pp 237-241.
- Gochee PA, Powell E E, Purdie D M, Pandeya N, Kelemen L, Shorthouse C, Jonsson J R and Kelly B (2004) Association Between Apolipoprotein E Epsilon4 and Neuropsychiatric Symptoms During Interferon Alpha Treatment for Chronic Hepatitis C. *Psychosomatics* 45: pp 49-57.
- Gohier B, Goeb J L, Rannou-Dubas K, Fouchard I, Cales P and Garre J B (2003) Hepatitis C, Alpha Interferon, Anxiety and Depression Disorders: a Prospective Study of 71 Patients. *World J Biol Psychiatry* 4: pp 115-118.
- Gray RJ, Pockaj B A and Kirkwood J M (2002) An Update on Adjuvant Interferon for Melanoma. *Cancer Control* 9: pp 16-21.
- Greenberg DB, Jonasch E, Gadd M A, Ryan B F, Everett J R, Sober A J, Mihm M A, Tanabe K K, Ott M and Haluska F G (2000) Adjuvant Therapy of Melanoma With Interferon-Alpha-2b Is Associated With Mania and Bipolar Syndromes. *Cancer* 89: pp 356-362.
- Grob JJ, Dreno B, de la S P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini J P, Lionnet S, Lok C, Chastang C and Bonerandi J J (1998) Randomised Trial of Interferon Alpha-2a As Adjuvant Therapy in Resected Primary Melanoma Thicker Than 1.5 Mm Without Clinically Detectable Node Metastases. French Cooperative Group on Melanoma. *Lancet* 351: pp 1905-1910.

- Gutterman JU (1994) Cytokine Therapeutics: Lessons From Interferon Alpha. *Proc Natl Acad Sci U S A* 91: pp 1198-1205.
- Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A and Pollmacher T (1999) Plasma Levels of Cytokines and Soluble Cytokine Receptors in Psychiatric Patients Upon Hospital Admission: Effects of Confounding Factors and Diagnosis. *J Psychiatr Res* 33: pp 407-418.
- Hagan H and Des J (2000) HIV and HCV Infection Among Injecting Drug Users. *Mt Sinai J Med* 67: pp 423-428.
- Hakansson A, Gustafsson B, Krysanter L, Hjelmqvist B, Rettrup B and Hakansson L (1999) Expression of ICAM-1 During IFN-Alpha-Based Treatment of Metastatic Malignant Melanoma: Relation to Tumor-Infiltrating Mononuclear Cells and Regressive Tumor Changes. *J Interferon Cytokine Res* 19: pp 171-177.
- Hancock BW, Harris S, Wheatley K and Gore M (2000) Adjuvant Interferon-Alpha in Malignant Melanoma: Current Status. *Cancer Treat Rev* 26: pp 81-89.
- Hannigan GE and Williams B R (1991) Signal Transduction by Interferon-Alpha Through Arachidonic Acid Metabolism. *Science* 251: pp 204-207.
- Haque SJ and Williams B R (1998) Signal Transduction in the Interferon System. *Semin Oncol* 25: pp 14-22.
- Haria M and Benfield P (1995) Interferon-Alpha-2a. A Review of Its Pharmacological Properties and Therapeutic Use in the Management of Viral Hepatitis. *Drugs* 50: pp 873-896.
- Hauschild A, Weichenthal M, Balda B R, Becker J C, Wolff H H, Tilgen W, Schulte K W, Ring J, Schadendorf D, Lischner S, Burg G and Dummer R (2003) Prospective Randomized Trial of Interferon Alfa-2b and Interleukin-2 As Adjuvant Treatment for Resected Intermediate- and High-Risk Primary Melanoma Without Clinically Detectable Node Metastasis. *J Clin Oncol* 21: pp 2883-2888.
- Hauser P, Khosla J, Aurora H, Laurin J, Kling M A, Hill J, Gulati M, Thornton A J, Schultz R L, Valentine A D, Meyers C A and Howell C D (2002) A Prospective Study

of the Incidence and Open-Label Treatment of Interferon-Induced Major Depressive Disorder in Patients With Hepatitis C. *Mol Psychiatry* 7: pp 942-947.

Heinz A, Hermann D, Smolka M N, Rieks M, Graf K J, Pohlau D, Kuhn W and Bauer M (2003) Effects of Acute Psychological Stress on Adhesion Molecules, Interleukins and Sex Hormones: Implications for Coronary Heart Disease. *Psychopharmacology (Berl)* 165: pp 111-117.

Hickey WF (1991) Migration of Hematogenous Cells Through the Blood-Brain Barrier and the Initiation of CNS Inflammation. *Brain Pathol* 1: pp 97-105.

Ho SB, Nguyen H, Tetrick L L, Opitz G A, Basara M L and Dieperink E (2001) Influence of Psychiatric Diagnoses on Interferon-Alpha Treatment for Chronic Hepatitis C in a Veteran Population. *Am J Gastroenterol* 96: pp 157-164.

Hori T, Katafuchi T, Take S and Shimizu N (1998) Neuroimmunomodulatory Actions of Hypothalamic Interferon-Alpha. *Neuroimmunomodulation* 5: pp 172-177.

Hu S, Sheng W S, Ehrlich L C, Peterson P K and Chao C C (2000) Cytokine Effects on Glutamate Uptake by Human Astrocytes. *Neuroimmunomodulation* 7: pp 153-159.

Hurlock EC (2001) Interferons: Potential Roles in Affect. *Med Hypotheses* 56: pp 558-566.

Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C and Manns M P (2001) Treatment of Acute Hepatitis C With Interferon Alfa-2b. *N Engl J Med* 345: pp 1452-1457.

Janssen HL, Brouwer J T, van der Mast R C and Schalm S W (1994) Suicide Associated With Alfa-Interferon Therapy for Chronic Viral Hepatitis. *J Hepatol* 21: pp 241-243.

Jaubert D, Hauteville D, Pelissier J F and Muzellec Y (1991) [Peripheral Neuropathy During Interferon Alpha Therapy]. *Presse Med* 20: pp 221-222.

Jereb B, Petric-Grabnar G, Klun B, Lamovec J, Skrbec M and Soos E (1994) Addition of IFN-Alpha to Treatment of Malignant Brain Tumors. *Acta Oncol* 33: pp 651-654.

- Jones SA and Rose-John S (2002) The Role of Soluble Receptors in Cytokine Biology: the Agonistic Properties of the SIL-6R/IL-6 Complex. *Biochim Biophys Acta* 1592: pp 251-263.
- Juengling FD, Ebert D, Gut O, Engelbrecht M A, Rasenack J, Nitzsche E U, Bauer J and Lieb K (2000) Prefrontal Cortical Hypometabolism During Low-Dose Interferon Alpha Treatment. *Psychopharmacology (Berl)* 152: pp 383-389.
- Juttler E, Tarabin V and Schwaninger M (2002) Interleukin-6 (IL-6): a Possible Neuromodulator Induced by Neuronal Activity. *Neuroscientist* 8: pp 268-275.
- Kamata M, Higuchi H, Yoshimoto M, Yoshida K and Shimizu T (2000) Effect of Single Intracerebroventricular Injection of Alpha-Interferon on Monoamine Concentrations in the Rat Brain. *Eur Neuropsychopharmacol* 10: pp 129-132.
- Kamei S, Sakai T, Matsuura M, Tanaka N, Kojima T, Arakawa Y, Matsukawa Y, Mizutani T, Oga K, Ohkubo H, Matsumura H and Hirayanagi K (2002) Alterations of Quantitative EEG and Mini-Mental State Examination in Interferon-Alpha-Treated Hepatitis C. *Eur Neurol* 48: pp 102-107.
- Kamei S, Tanaka N, Mastuura M, Arakawa Y, Kojima T, Matsukawa Y, Takasu T and Moriyama M (1999) Blinded, Prospective, and Serial Evaluation by Quantitative-EEG in Interferon-Alpha-Treated Hepatitis-C. *Acta Neurol Scand* 100: pp 25-33.
- Kelley KW, Bluth R M, Dantzer R, Zhou J H, Shen W H, Johnson R W and Broussard S R (2003) Cytokine-Induced Sickness Behavior. *Brain Behav Immun* 17 Suppl 1: pp S112-S118.
- Kenis G and Maes M (2002) Effects of Antidepressants on the Production of Cytokines. *Int J Neuropsychopharmacol* 5: pp 401-412.
- Khan NU, Pulford K A, Farquharson M A, Howatson A, Stewart C, Jackson R, McNicol A M and Foulis A K (1989) The Distribution of Immunoreactive Interferon-Alpha in Normal Human Tissues. *Immunology* 66: pp 201-206.
- Kirkwood JM (1991) Studies of Interferons in the Therapy of Melanoma. *Semin Oncol* 18: pp 83-90.

Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S and Stover L (2002a) Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy. *J Clin Oncol* 20: pp 3703-3718.

Kirkwood JM and Ernstoff M (1985) Melanoma: Therapeutic Options With Recombinant Interferons. *Semin Oncol* 12: pp 7-12.

Kirkwood JM, Richards T, Zarour H M, Sosman J, Ernstoff M, Whiteside T L, Ibrahim J, Blum R, Wieand S and Mascari R (2002b) Immunomodulatory Effects of High-Dose and Low-Dose Interferon Alpha2b in Patients With High-Risk Resected Melanoma: the E2690 Laboratory Corollary of Intergroup Adjuvant Trial E1690. *Cancer* 95: pp 1101-1112.

Kirkwood JM, Strawderman M H, Ernstoff M S, Smith T J, Borden E C and Blum R H (1996) Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. *J Clin Oncol* 14: pp 7-17.

Kneier AW (2003) Coping With Melanoma--Ten Strategies That Promote Psychological Adjustment. *Surg Clin North Am* 83: pp 417-430.

Kraus J, Oschmann P, Engelhardt B, Schiel C, Hornig C, Bauer R, Kern A, Traupe H and Dorndorf W (1998) Soluble and Cell Surface ICAM-1 As Markers for Disease Activity in Multiple Sclerosis. *Acta Neurol Scand* 98: pp 102-109.

Kraus MR, Schafer A, Faller H, Csef H and Scheurlen M (2002) Paroxetine for the Treatment of Interferon-Alpha-Induced Depression in Chronic Hepatitis C. *Aliment Pharmacol Ther* 16: pp 1091-1099.

Kraus MR, Schafer A and Scheurlen M (2001) Paroxetine for the Prevention of Depression Induced by Interferon Alfa. *N Engl J Med* 345: pp 375-376.

Kronfol Z and Remick D G (2000) Cytokines and the Brain: Implications for Clinical Psychiatry. *Am J Psychiatry* 157: pp 683-694.

Lanquillon S, Krieg J C, Bening-Abu-Shach U and Vedder H (2000) Cytokine Production and Treatment Response in Major Depressive Disorder. *Neuropsychopharmacology* 22: pp 370-379.

Lee SJ and Benveniste E N (1999) Adhesion Molecule Expression and Regulation on Cells of the Central Nervous System. *J Neuroimmunol* 98: pp 77-88.

Leonard BE (2001a) Changes in the Immune System in Depression and Dementia: Causal or Co-Incidental Effects? *Int J Dev Neurosci* 19: pp 305-312.

Leonard BE (2001b) The Immune System, Depression and the Action of Antidepressants. *Prog Neuropsychopharmacol Biol Psychiatry* 25: pp 767-780.

Leonard BE and Song C (1996) Stress and the Immune System in the Etiology of Anxiety and Depression. *Pharmacol Biochem Behav* 54: pp 299-303.

Leonard BE and Song C (1999) Stress, Depression, and the Role of Cytokines. *Adv Exp Med Biol* 461: pp 251-265.

Lesperance F, Frasere-Smith N, Theroux P and Irwin M (2004) The Association Between Major Depression and Levels of Soluble Intercellular Adhesion Molecule 1, Interleukin-6, and C-Reactive Protein in Patients With Recent Acute Coronary Syndromes. *Am J Psychiatry* 161: pp 271-277.

Levenson JL and Fallon H J (1993) Fluoxetine Treatment of Depression Caused by Interferon-Alpha. *Am J Gastroenterol* 88: pp 760-761.

Licinio J, Kling M A and Hauser P (1998) Cytokines and Brain Function: Relevance to Interferon-Alpha-Induced Mood and Cognitive Changes. *Semin Oncol* 25: pp 30-38.

Locarnini SA and Bartholomeusz A (2002) Advances in Hepatitis C: What Is Coming in the Next 5 Years? *J Gastroenterol Hepatol* 17: pp 442-447.

Lynch P, Peters M, Quigley M, Sreenarasaimhiah J and Cladwell C (1998) Impact of Psychiatric Disorders on Treatment of Patients With Hepatitis C. *Gastroenterol* 114, (suppl.)

MacKie RM (2002) Risk Factors for the Development of Primary Cutaneous Malignant Melanoma. *Dermatol Clin* 20: pp 597-600.

Maes M (1994) Cytokines in Major Depression. *Biol Psychiatry* 36: pp 498-499.

- Maes M (1995) Evidence for an Immune Response in Major Depression: a Review and Hypothesis. *Prog Neuropsychopharmacol Biol Psychiatry* 19: pp 11-38.
- Maes M (1999) Major Depression and Activation of the Inflammatory Response System. *Adv Exp Med Biol* 461: pp 25-46.
- Maes M (2001) The Immunoregulatory Effects of Antidepressants. *Hum Psychopharmacol* 16: pp 95-103.
- Maes M and Bonaccorso S (2004) Lower Activities of Serum Peptidases Predict Higher Depressive and Anxiety Levels Following Interferon-Alpha-Based Immunotherapy in Patients With Hepatitis C. *Acta Psychiatr Scand* 109: pp 126-131.
- Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C and Meltzer H (2001) Treatment With Interferon-Alpha (IFN Alpha) of Hepatitis C Patients Induces Lower Serum Dipeptidyl Peptidase IV Activity, Which Is Related to IFN Alpha-Induced Depressive and Anxiety Symptoms and Immune Activation. *Mol Psychiatry* 6: pp 475-480.
- Maes M, Bosmans E, Calabrese J, Smith R and Meltzer H Y (1995a) Interleukin-2 and Interleukin-6 in Schizophrenia and Mania: Effects of Neuroleptics and Mood Stabilizers. *J Psychiatr Res* 29: pp 141-152.
- Maes M, Bosmans E, Meltzer H Y, Scharpe S and Suy E (1993a) Interleukin-1 Beta: a Putative Mediator of HPA Axis Hyperactivity in Major Depression? *Am J Psychiatry* 150: pp 1189-1193.
- Maes M, De Ruyter M, Claes R and Suy E (1988) Self Rated Depression in Relation to DSM-III Classification: a Statistical Isolinear Multiple Components Analysis. *Acta Psychiatr Scand* 77: pp 27-31.
- Maes M, Delange J, Ranjan R, Meltzer H Y, Desnyder R, Cooremans W and Scharpe S (1997) Acute Phase Proteins in Schizophrenia, Mania and Major Depression: Modulation by Psychotropic Drugs. *Psychiatry Res* 66: pp 1-11.

- Maes M, Meltzer H Y, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R and Desnyder R (1995b) Increased Plasma Concentrations of Interleukin-6, Soluble Interleukin-6, Soluble Interleukin-2 and Transferrin Receptor in Major Depression. *J Affect Disord* 34: pp 301-309.
- Maes M, Scharpe S, Meltzer H Y, Okayli G, Bosmans E, D'Hondt P, Vanden Bossche B V and Cosyns P (1994) Increased Neopterin and Interferon-Gamma Secretion and Lower Availability of L-Tryptophan in Major Depression: Further Evidence for an Immune Response. *Psychiatry Res* 54: pp 143-160.
- Maes M, Song C, Lin A H, Pioli R, Kenis G, Kubera M and Bosmans E (1999) In Vitro Immunoregulatory Effects of Lithium in Healthy Volunteers. *Psychopharmacology (Berl)* 143: pp 401-407.
- Maes M, Stevens W J, Declerck L S, Bridts C H, Peeters D, Schotte C and Cosyns P (1993b) Significantly Increased Expression of T-Cell Activation Markers (Interleukin-2 and HLA-DR) in Depression: Further Evidence for an Inflammatory Process During That Illness. *Prog Neuropsychopharmacol Biol Psychiatry* 17: pp 241-255.
- Maes M, Vandoolaeghe E, Ranjan R, Bosmans E, Bergmans R and Desnyder R (1995c) Increased Serum Interleukin-1-Receptor-Antagonist Concentrations in Major Depression. *J Affect Disord* 36: pp 29-36.
- Malaguarnera M, Di F, I, Restuccia S, Pistone G, Ferlito L and Rampello L (1998) Interferon Alpha-Induced Depression in Chronic Hepatitis C Patients: Comparison Between Different Types of Interferon Alpha. *Neuropsychobiology* 37: pp 93-97.
- Malaguarnera M, Laurino A, Di F, I, Pistone G, Castorina M, Guccione N and Rampello L (2001) Neuropsychiatric Effects and Type of IFN-Alpha in Chronic Hepatitis C. *J Interferon Cytokine Res* 21: pp 273-278.
- Malek-Ahmadi P (2001) Mood Disorders Associated With Interferon Treatment: Theoretical and Practical Considerations. *Ann Pharmacother* 35: pp 489-495.
- Malik UR, Makower D F and Wadler S (2001) Interferon-Mediated Fatigue. *Cancer* 92: pp 1664-1668.

Manns MP, McHutchison J G, Gordon S C, Rustgi V K, Shiffman M, Reindollar R, Goodman Z D, Koury K, Ling M and Albrecht J K (2001) Peginterferon Alfa-2b Plus Ribavirin Compared With Interferon Alfa-2b Plus Ribavirin for Initial Treatment of Chronic Hepatitis C: a Randomised Trial. *Lancet* 358: pp 958-965.

Marks R (2000) Epidemiology of Melanoma. *Clin Exp Dermatol* 25: pp 459-463.

Mathei C, Buntinx F and van Damme P (2002) Seroprevalence of Hepatitis C Markers Among Intravenous Drug Users in Western European Countries: a Systematic Review. *J Viral Hepat* 9: pp 157-173.

Mayr N, Zeitlhofer J, Deecke L, Fritz E, Ludwig H and Gisslinger H (1999) Neurological Function During Long-Term Therapy With Recombinant Interferon Alpha. *J Neuropsychiatry Clin Neurosci* 11: pp 343-348.

McDaniel JS, Musselman D L, Porter M R, Reed D A and Nemeroff C B (1995) Depression in Patients With Cancer. Diagnosis, Biology, and Treatment. *Arch Gen Psychiatry* 52: pp 89-99.

McDonald EM, Mann A H and Thomas H C (1987) Interferons As Mediators of Psychiatric Morbidity. An Investigation in a Trial of Recombinant Alpha-Interferon in Hepatitis-B Carriers. *Lancet* 2: pp 1175-1178.

McHutchison JG and Fried M W (2003) Current Therapy for Hepatitis C: Pegylated Interferon and Ribavirin. *Clin Liver Dis* 7: pp 149-161.

McHutchison JG, Gordon S C, Schiff E R, Shiffman M L, Lee W M, Rustgi V K, Goodman Z D, Ling M H, Cort S and Albrecht J K (1998) Interferon Alfa-2b Alone or in Combination With Ribavirin As Initial Treatment for Chronic Hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med* 339: pp 1485-1492.

McHutchison JG, Manns M, Patel K, Poynard T, Lindsay K L, Trepo C, Dienstag J, Lee W M, Mak C, Garaud J J and Albrecht J K (2002) Adherence to Combination Therapy Enhances Sustained Response in Genotype-1-Infected Patients With Chronic Hepatitis C. *Gastroenterology* 123: pp 1061-1069.

Memon MI and Memon M A (2002) Hepatitis C: an Epidemiological Review. *J Viral Hepat* 9: pp 84-100.

Merimsky O and Chaitchik S (1992) Neurotoxicity of Interferon-Alpha. *Anticancer Drugs* 3: pp 567-570.

Meyer T, Marg A, Lemke P, Wiesner B and Vinkemeier U (2003) DNA Binding Controls Inactivation and Nuclear Accumulation of the Transcription Factor Stat1. *Genes Dev* 17: pp 1992-2005.

Meyers CA, Obbens E A, Scheibel R S and Moser R P (1991a) Neurotoxicity of Intraventricularly Administered Alpha-Interferon for Leptomeningeal Disease. *Cancer* 68: pp 88-92.

Meyers CA, Scheibel R S and Forman A D (1991b) Persistent Neurotoxicity of Systemically Administered Interferon-Alpha. *Neurology* 41: pp 672-676.

Miller IW, Norman W H, Bishop S B and Dow M G (1986) The Modified Scale for Suicidal Ideation: Reliability and Validity. *J Consult Clin Psychol* 54: pp 724-725.

Miller VS, Zwiener R J and Fielman B A (1994) Interferon-Associated Refractory Status Epilepticus. *Pediatrics* 93: pp 511-512.

Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M and Mitamura K (1999) Depression From Interferon Therapy in Patients With Hepatitis C. *Am J Psychiatry* 156: pp 1120.

Mohr DC, Goodkin D E, Likosky W, Gatto N, Baumann K A and Rudick R A (1997) Treatment of Depression Improves Adherence to Interferon Beta-1b Therapy for Multiple Sclerosis. *Arch Neurol* 54: pp 531-533.

Mohr DC, Likosky W, Boudewyn A C, Marietta P, Dwyer P, Van der W J and Goodkin D E (1998) Side Effect Profile and Adherence to in the Treatment of Multiple Sclerosis With Interferon Beta-1a. *Mult Scler* 4: pp 487-489.

Mohr P, Weichenthal M and Hauschild A (2003) Adjuvant Therapy in Melanoma. *Onkologie* 26: pp 227-233.

- Montero-Julian FA (2001) The Soluble IL-6 Receptors: Serum Levels and Biological Function. *Cell Mol Biol (Noisy-le-grand)* 47: pp 583-597.
- Montgomery, S. A. and Asperg, M. (1979) A new depression rating scale designed to be sensitive to change. *Br.J.Psychiatry* 134, pp 382-389.
- Monto A and Wright T L (2001) The Epidemiology and Prevention of Hepatocellular Carcinoma. *Semin Oncol* 28: pp 441-449.
- Morikawa O, Sakai N, Obara H and Saito N (1998) Effects of Interferon-Alpha, Interferon-Gamma and CAMP on the Transcriptional Regulation of the Serotonin Transporter. *Eur J Pharmacol* 349: pp 317-324.
- Müller N and Ackenheil M (1998) Psychoneuroimmunology and the Cytokine Action in the CNS: Implications for Psychiatric Disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 22: pp 1-33.
- Müller N, Empl M, Riedel M, Schwarz M and Ackenheil M (1997) Neuroleptic Treatment Increases Soluble IL-2 Receptors and Decreases Soluble IL-6 Receptors in Schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 247: pp 308-313.
- Müller N, Riedel M, Ackenheil M and Schwarz M J (1999) The Role of Immune Function in Schizophrenia: an Overview. *Eur Arch Psychiatry Clin Neurosci* 249 Suppl 4: pp 62-68.
- Müller N, Riedel M, Gruber R, Ackenheil M and Schwarz M J (2000) The Immune System and Schizophrenia. An Integrative View. *Ann N Y Acad Sci* 917: pp 456-467.
- Müller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, Ulmschneider M, Engel R R, Moller H J and Schwarz M J (2002) Beneficial Antipsychotic Effects of Celecoxib Add-on Therapy Compared to Risperidone Alone in Schizophrenia. *Am J Psychiatry* 159: pp 1029-1034.
- Musselman DL, Lawson D H, Gumnick J F, Manatunga A K, Penna S, Goodkin R S, Greiner K, Nemeroff C B and Miller A H (2001a) Paroxetine for the Prevention of Depression Induced by High-Dose Interferon Alfa. *N Engl J Med* 344: pp 961-966.

Musselman DL, Miller A H, Porter M R, Manatunga A, Gao F, Penna S, Pearce B D, Landry J, Glover S, McDaniel J S and Nemeroff C B (2001b) Higher Than Normal Plasma Interleukin-6 Concentrations in Cancer Patients With Depression: Preliminary Findings. *Am J Psychiatry* 158: pp 1252-1257.

National Institute of Mental Health (1970). CGI. Global Clinical Impressions. Guy, W. EDCEU Assassement in Psychopharmacology. 1970. Rockville, Maryland.

NIH (1997) Management of Hepatitis C: NIH Conensus Statment. *Hepatology* 15: pp 1-41.

NIH (2002) National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C - 2002. *Hepatology* 36: pp S3-20.

Nozaki O, Takagi C, Takaoka K, Takata T and Yoshida M (1997) Psychiatric Manifestations Accompanying Interferon Therapy for Patients With Chronic Hepatitis C: an Overview of Cases in Japan. *Psychiatry Clin Neurosci* 51: pp 175-180.

Ohara Y, McCarron R M, Hoffman T T, Sugano H, Bembry J, Lenz F A and Spatz M (2000) Adrenergic Mediation of TNF Alpha-Stimulated ICAM-1 Expression on Human Brain Microvascular Endothelial Cells. *Acta Neurochir Suppl* 76: pp 117-120.

Overall, J. E. and Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. *Psychological Reports* 10: pp 799-812.

Palitzsch KD, Hottentrager B, Schlottmann K, Frick E, Holstege A, Scholmerich J and Jilg W (1999) Prevalence of Antibodies Against Hepatitis C Virus in the Adult German Population. *Eur J Gastroenterol Hepatol* 11: pp 1215-1220.

Pan W, Banks W A and Kastin A J (1997) Permeability of the Blood-Brain and Blood-Spinal Cord Barriers to Interferons. *J Neuroimmunol* 76: pp 105-111.

Pariante CM, Landau S and Carpiniello B (2002) Interferon Alfa-Induced Adverse Effects in Patients With a Psychiatric Diagnosis. *N Engl J Med* 347: pp 148-149.

Pariante CM, Orru M G, Baita A, Farci M G and Carpiniello B (1999) Treatment With Interferon-Alpha in Patients With Chronic Hepatitis and Mood or Anxiety Disorders. *Lancet* 354: pp 131-132.

- Patten SB (2001) What Is the Best Approach to Treating Interferon-Induced Depression in People With Multiple Sclerosis? *J Psychiatry Neurosci* 26: pp 66.
- Patten SB and Metz L M (2002) Interferon Beta1a and Depression in Secondary Progressive MS: Data From the SPECTRIMS Trial. *Neurology* 59: pp 744-746.
- Pavol MA, Meyers C A, Rexer J L, Valentine A D, Mattis P J and Talpaz M (1995) Pattern of Neurobehavioral Deficits Associated With Interferon Alfa Therapy for Leukemia. *Neurology* 45: pp 947-950.
- Pehamberger H, Soyer H P, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Aubock J, Fritsch P, Kerl H and Wolff K (1998) Adjuvant Interferon Alfa-2a Treatment in Resected Primary Stage II Cutaneous Melanoma. Austrian Malignant Melanoma Cooperative Group. *J Clin Oncol* 16: pp 1425-1429.
- Pestka S (2000) The Human Interferon Alpha Species and Receptors. *Biopolymers* 55: pp 254-287.
- Plotkin SR, Banks W A and Kastin A J (1996) Comparison of Saturable Transport and Extracellular Pathways in the Passage of Interleukin-1 Alpha Across the Blood-Brain Barrier. *J Neuroimmunol* 67: pp 41-47.
- Plotkin SR, Banks W A, Maness L M and Kastin A J (2000) Differential Transport of Rat and Human Interleukin-1alpha Across the Blood-Brain Barrier and Blood-Testis Barrier in Rats. *Brain Res* 881: pp 57-61.
- Poynard T, Marcellin P, Lee S S, Niederau C, Minuk G S, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C and Albrecht J (1998) Randomised Trial of Interferon Alpha2b Plus Ribavirin for 48 Weeks or for 24 Weeks Versus Interferon Alpha2b Plus Placebo for 48 Weeks for Treatment of Chronic Infection With Hepatitis C Virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet* 352: pp 1426-1432.
- Prange HW (1994) Interferon-Alpha. Zum Problem der persistierenden Neurotoxizität. *Dt Ärztebl* 91: pp 3420-3427.
- Rapaport MH and Manji H K (2001) The Effects of Lithium on Ex Vivo Cytokine Production. *Biol Psychiatry* 50: pp 217-224.

Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A and Pollmacher T (2001) Cytokine-Associated Emotional and Cognitive Disturbances in Humans. *Arch Gen Psychiatry* 58: pp 445-452.

Renault PF and Hoofnagle J H (1989) Side Effects of Alpha Interferon. *Semin Liver Dis* 9: pp 273-277.

Renault PF, Hoofnagle J H, Park Y, Mullen K D, Peters M, Jones D B, Rustgi V and Jones E A (1987) Psychiatric Complications of Long-Term Interferon Alfa Therapy. *Arch Intern Med* 147: pp 1577-1580.

Rieckmann P, Altenhofen B, Riegel A, Baudewig J and Felgenhauer K (1997) Soluble Adhesion Molecules (SVCAM-1 and SICAM-1) in Cerebrospinal Fluid and Serum Correlate With MRI Activity in Multiple Sclerosis. *Ann Neurol* 41: pp 326-333.

Rieckmann P, Nunke K, Burchhardt M, Albrecht M, Wiltfang J, Ulrich M and Felgenhauer K (1993) Soluble Intercellular Adhesion Molecule-1 in Cerebrospinal Fluid: an Indicator for the Inflammatory Impairment of the Blood-Cerebrospinal Fluid Barrier. *J Neuroimmunol* 47: pp 133-140.

Risau W, Esser S and Engelhardt B (1998) Differentiation of Blood-Brain Barrier Endothelial Cells. *Pathol Biol (Paris)* 46: pp 171-175.

Rothermundt M, Arolt V, Leadbeater J, Peters M, Rudolf S and Kirchner H (2000) Cytokine Production in Unmedicated and Treated Schizophrenic Patients. *Neuroreport* 11: pp 3385-3388.

Rothermundt M, Arolt V, Weitzsch C, Eckhoff D and Kirchner H (1998) Immunological Dysfunction in Schizophrenia: a Systematic Approach. *Neuropsychobiology* 37: pp 186-193.

Roy K, Hay G, Andragetti R, Taylor A, Goldberg D and Wiessing L (2002) Monitoring Hepatitis C Virus Infection Among Injecting Drug Users in the European Union: a Review of the Literature. *Epidemiol Infect* 129: pp 577-585.

Sammut S, Bethus I, Goodall G and Muscat R (2002) Antidepressant Reversal of Interferon-Alpha-Induced Anhedonia. *Physiol Behav* 75: pp 765-772.

Schäfer, M. (2002) [Neuro-psychiatric side effects of interferon-alpha in drug addicts: reasons, frequency and therapy.]. *Suchttherapie* 3 suppl.: pp 72-77.

Schäfer M, Boetsch T and Laakmann G (2000a) Psychosis in a Methadone-Substituted Patient During Interferon-Alpha Treatment of Hepatitis C. *Addiction* 95: pp 1101-1104.

Schäfer M, Engelbrecht M A, Gut O, Fiebich B L, Bauer J, Schmidt F, Grunze H and Lieb K (2002) Interferon Alpha (IFNalpha) and Psychiatric Syndromes: a Review. *Prog Neuropsychopharmacol Biol Psychiatry* 26: pp 731-746.

Schäfer M, Horn M, Schmidt F, Schmid-Wendtner MH, Volkenandt M, Ackenheil M, Mueller N, Schwarz MJ (2004c) Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with Interferon- α . *Brain Behav Immun*, in press

Schäfer M, Messer T, Wegner U, Schmid-Wendtner M H and Volkenandt M (1999) [Psychiatric Side Effects During Adjuvant Therapy With Interferon-Alpha in Patients With Malignant Melanoma. Clinical Evaluation As Well As Diagnostic and Therapeutic Possibilities]. *Hautarzt* 50: pp 654-658.

Schäfer, M., Schindlbeck, N., Kloth, A., Wegner, U., and Soyka, M. (2000c) [Treatment of chronic hepatitis C in former iv. drug addicts and patients in methadone maintenance programs.]. *Suchtmed* 2: pp 13-23.

Schäfer M, Schmidt F, Amann B, Schlosser S, Loeschke K and Grunze H (2000b) Adding Low-Dose Antidepressants to Interferon Alpha Treatment for Chronic Hepatitis C Improved Psychiatric Tolerability in a Patient With Schizoaffective Psychosis. *Neuropsychobiology* 42 Suppl 1: pp 43-45.

Schäfer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A and Loeschke K (2003a) Adherence and Mental Side Effects During Hepatitis C Treatment With Interferon Alfa and Ribavirin in Psychiatric Risk Groups. *Hepatology* 37: pp 443-451.

Schäfer M, Schwaiger M, Pich M, Lieb K and Heinz A (2003b) Neurotransmitter Changes by Interferon-Alpha and Therapeutic Implications. *Pharmacopsychiatry* 36 Suppl 3: pp S203-S206.

Schäfer M and Schwaiger M (2003) [Incidence, Pathoetiology and Treatment of Interferon-Alpha Induced Neuro-Psychiatric Side Effects]. *Fortschr Neurol Psychiatr* 71: pp 469-476.

Schäfer M, Schmidt F, Horn M; Schmid-Wendtner MH; Volkenandt M (2004a) Depression during treatment with interferon alpha. *Psychosomatics* 2: pp 176

Schäfer M, Heinz A, Backmund M (2004b). Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? *Addiction*, in press

Schindler C (1995) Cytokine Signal Transduction. *Receptor* 5: pp 51-62.

Schofield PE, Butow P N, Thompson J F, Tattersall M H, Beeney L J and Dunn S M (2003) Psychological Responses of Patients Receiving a Diagnosis of Cancer. *Ann Oncol* 14: pp 48-56.

Schramm TM, Lawford B R, Macdonald G A and Cooksley W G (2000) Sertraline Treatment of Interferon-Alfa-Induced Depressive Disorder. *Med J Aust* 173: pp 359-361.

Schrott LM and Crnic L S (1996) Increased Anxiety Behaviors in Autoimmune Mice. *Behav Neurosci* 110: pp 492-502.

Schwarz MJ, Chiang S, Müller N and Ackenheil M (2001a) T-Helper-1 and T-Helper-2 Responses in Psychiatric Disorders. *Brain Behav Immun* 15: pp 340-370.

Schwarz MJ, Müller N, Riedel M and Ackenheil M (2001b) The Th2-Hypothesis of Schizophrenia: a Strategy to Identify a Subgroup of Schizophrenia Caused by Immune Mechanisms. *Med Hypotheses* 56: pp 483-486.

Schwarz MJ, Riedel M, Ackenheil M and Müller N (2000) Decreased Levels of Soluble Intercellular Adhesion Molecule-1 (SICAM-1) in Unmedicated and Medicated Schizophrenic Patients. *Biol Psychiatry* 47: pp 29-33.

Shad J, Person J and Brann O. (2000) How Often Are Referred Chronic Hepatitis C Patients Candidates for Antiviral Therapy. *Hepatology* 32.

Sharief MK, Noori M A, Ciardi M, Cirelli A and Thompson E J (1993) Increased Levels of Circulating ICAM-1 in Serum and Cerebrospinal Fluid of Patients With

Active Multiple Sclerosis. Correlation With TNF-Alpha and Blood-Brain Barrier Damage. *J Neuroimmunol* 43: pp 15-21.

Shiozawa S, Kuroki Y, Kim M, Hirohata S and Ogino T (1992) Interferon-Alpha in Lupus Psychosis. *Arthritis Rheum* 35: pp 417-422.

Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M and Wiktorowicz K (1996) Indicators of Immune Activation in Major Depression. *Psychiatry Res* 64: pp 161-167.

Sollner W, Zingg-Schir M, Rumpold G, Mairinger G and Fritsch P (1998) Need for Supportive Counselling--the Professionals' Versus the Patients' Perspective. A Survey in a Representative Sample of 236 Melanoma Patients. *Psychother Psychosom* 67: pp 94-104.

Song C, Lin A, Bonaccorso S, Heide C, Verkerk R, Kenis G, Bosmans E, Scharpe S, Whelan A, Cosyns P, De Jongh R and Maes M (1998) The Inflammatory Response System and the Availability of Plasma Tryptophan in Patients With Primary Sleep Disorders and Major Depression. *J Affect Disord* 49: pp 211-219.

Strite D, Valentine A D and Meyers C A (1997) Manic Episodes in Two Patients Treated With Interferon Alpha. *J Neuropsychiatry Clin Neurosci* 9: pp 273-276.

Suter CC, Westmoreland B F, Sharbrough F W and Hermann R C, Jr. (1984) Electroencephalographic Abnormalities in Interferon Encephalopathy: a Preliminary Report. *Mayo Clin Proc* 59: pp 847-850.

Sylvestre DL (2002) Treating Hepatitis C in Methadone Maintenance Patients: an Interim Analysis. *Drug Alcohol Depend* 67: pp 117-123.

Taruschio G, Santarini G and Sica G (1996) Psychiatric Disorders in Hepatitis C Virus Related Chronic Liver Disease. *Gastroenterology* 110.

Taylor JL and Grossberg S E (1998) The Effects of Interferon-Alpha on the Production and Action of Other Cytokines. *Semin Oncol* 25: pp 23-29.

Taylor LE, Costello T, Alt E, Yates G and Tashima K (2002) Psychiatric Illness and Illicit Drugs As Barriers to Hepatitis C Treatment Among HIV/Hepatitis C Virus Co-Infected Individuals. *AIDS* 16: pp 1700-1701.

Thomas AJ, Ferrier I N, Kalaria R N, Woodward S A, Ballard C, Oakley A, Perry R H and O'Brien J T (2000) Elevation in Late-Life Depression of Intercellular Adhesion Molecule-1 Expression in the Dorsolateral Prefrontal Cortex. *Am J Psychiatry* 157: pp 1682-1684.

Thorpe LE, Ouellet L J, Hershow R, Bailey S L, Williams I T, Williamson J, Monterroso E R and Garfein R S (2002) Risk of Hepatitis C Virus Infection Among Young Adult Injection Drug Users Who Share Injection Equipment. *Am J Epidemiol* 155: pp 645-653.

Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F, Coppola R C, Sauleda S, Thursz M R, Tillmann H, Alberti A, Braconier J H, Esteban J I, Hadziyannis S J, Manns M P, Saracco G, Thomas H C and Trepo C (2000) Epidemiology of Hepatitis C Virus Infection in Seven European Union Countries: a Critical Analysis of the Literature. HENCORE Group. (Hepatitis C European Network for Co-Operative Research). *Eur J Gastroenterol Hepatol* 12: pp 667-678.

Uze G, Di Marco S, Mouchel-Vielh E, Monneron D, Bandu M T, Horisberger M A, Dorques A, Lutfalla G and Mogensen K E (1994) Domains of Interaction Between Alpha Interferon and Its Receptor Components. *J Mol Biol* 243: pp 245-257.

Valentine AD and Meyers C A (1995) Successful Treatment of Interferon-Alpha-Induced Mood Disorder With Nortriptyline. *Psychosomatics* 36: pp 418-419.

Valentine AD, Meyers C A, Kling M A, Richelson E and Hauser P (1998) Mood and Cognitive Side Effects of Interferon-Alpha Therapy. *Semin Oncol* 25: pp 39-47.

Valentine AD, Meyers C A and Talpaz M (1995) Treatment of Neurotoxic Side Effects of Interferon-Alpha With Naltrexone. *Cancer Invest* 13: pp 561-566.

Valentini P, Mariotti P, Ngalikpima C J, Angelone D F and Ranno O (2001) Seizures in an Interferon-Treated Child. *Dig Liver Dis* 33: pp 363-365.

Van Ameijden EJ, Van den Hoek J A, Mientjes G H and Coutinho R A (1993) A Longitudinal Study on the Incidence and Transmission Patterns of HIV, HBV and HCV Infection Among Drug Users in Amsterdam. *Eur J Epidemiol* 9: pp 255-262.

- van de SA and van der Saag P T (1996) Intercellular Adhesion Molecule-1. *J Mol Med* 74: pp 13-33.
- Van Thiel DH, Anantharaju A and Creech S (2003) Response to Treatment of Hepatitis C in Individuals With a Recent History of Intravenous Drug Abuse. *Am J Gastroenterol* 98: pp 2281-2288.
- Van Thiel DH, Friedlander L, Molloy P J, Fagiuoli S, Kania R J and Caraceni P (1995) Interferon-Alpha Can Be Used Successfully in Patients With Hepatitis C Virus-Positive Chronic Hepatitis Who Have a Psychiatric Illness. *Eur J Gastroenterol Hepatol* 7: pp 165-168.
- van West D and Maes M (1999) Activation of the Inflammatory Response System: A New Look at the Etiopathogenesis of Major Depression. *Neuroendocrinol Lett* 20: pp 11-17.
- Vinkemeier U, Moarefi I, Darnell J E, Jr. and Kuriyan J (1998) Structure of the Amino-Terminal Protein Interaction Domain of STAT-4. *Science* 279: pp 1048-1052.
- Waguespack PJ, Banks W A and Kastin A J (1994) Interleukin-2 Does Not Cross the Blood-Brain Barrier by a Saturable Transport System. *Brain Res Bull* 34: pp 103-109.
- Walter MR, Bordens R, Nagabhushan T L, Williams B R, Herberman R B, Dinarello C A, Borden E C, Trotta P P, Pestka S and Pfeffer L M (1998) Review of Recent Developments in the Molecular Characterization of Recombinant Alfa Interferons on the 40th Anniversary of the Discovery of Interferon. *Cancer Biother Radiopharm* 13: pp 143-154.
- Weinrieb RM, Auriacombe M, Lynch K G, Chang K M and Lewis J D (2003) A Critical Review of Selective Serotonin Reuptake Inhibitor-Associated Bleeding: Balancing the Risk of Treating Hepatitis C-Infected Patients. *J Clin Psychiatry* 64: pp 1502-1510.
- Weiss J, Herbst R A and Kapp A (2000) [Malignant Melanoma of the Skin. Pathogenesis, Clinical Aspects and Prognosis]. *Versicherungsmedizin* 52: pp 7-12.
- White RR, Stanley W E, Johnson J L, Tyler D S and Seigler H F (2002) Long-Term Survival in 2,505 Patients With Melanoma With Regional Lymph Node Metastasis. *Ann Surg* 235: pp 879-887.

Wichers M and Maes M (2002) The Psychoneuroimmuno-Pathophysiology of Cytokine-Induced Depression in Humans. *Int J Neuropsychopharmacol* 5: pp 375-388.

Wichers MC and Maes M (2004) The Role of Indoleamine 2,3-Dioxygenase (IDO) in the Pathophysiology of Interferon-Alpha-Induced Depression. *J Psychiatry Neurosci* 29: pp 11-17.

Wiranowska M, Gonzalvo A A, Saporta S, Gonzalez O R and Prockop L D (1992) Evaluation of Blood-Brain Barrier Permeability and the Effect of Interferon in Mouse Glioma Model. *J Neurooncol* 14: pp 225-236.

Wiranowska M, Prockop L D, Naidu A K, Saporta S, Kori S and Kulkarni A P (1994) Interferon Entry Through the Blood-Brain Barrier in Glioma and Its Effect on Lipoxygenase Activity. *Anticancer Res* 14: pp 1121-1126.

Wiranowska M, Wilson T C, Thompson K and Prockop L D (1989) Cerebral Interferon Entry in Mice After Osmotic Alteration of Blood-Brain Barrier. *J Interferon Res* 9: pp 353-362.

Wong D, Prameya R and Dorovini-Zis K (1999) In Vitro Adhesion and Migration of T Lymphocytes Across Monolayers of Human Brain Microvessel Endothelial Cells: Regulation by ICAM-1, VCAM-1, E-Selectin and PECAM-1. *J Neuropathol Exp Neurol* 58: pp 138-152.

Wright IA (2000) Monitoring Depression in Patients Undergoing Alpha-Interferon and Ribavirin Therapy for Hepatitis C. *Gastroenterol Nurs* 23: pp 275-280.

Yamada T and Yamanaka I (1995) Microglial Localization of Alpha-Interferon Receptor in Human Brain Tissues. *Neurosci Lett* 189: pp 73-76.

Yoshida K, Higuchi H, Takahashi H and Shimizu T (2003) Favorable Effect of Milnacipran on Depression Induced by Interferon-Alpha. *J Neuropsychiatry Clin Neurosci* 15: pp 242-243.

Zav'Yalov VP and Zav'Yalova G A (1997) Interferons Alpha/Beta and Their Receptors: Place in the Hierarchy of Cytokines. *APMIS* 105: pp 161-186.

Zdilar D, Franco-Bronson K, Buchler N, Locala J A and Younossi Z M (2000) Hepatitis C, Interferon Alfa, and Depression. *Hepatology* 31: pp 1207-1211.

Zerssen, D. v. Beschwerdeskala bei Depressionen (1973). *Therapiewoche* 46: pp 4426-4440.

Zung WW, Richards C B and Short M J (1965) Self-Rating Depression Scale in an Outpatient Clinic. Further Validation of the SDS. *Arch Gen Psychiatry* 13: pp 508-515.